All In Biotech

Drug Trial Radar · NCT07677215

ACB and iPACK Blocks With Intravenous Dexamethasone and Perineural Dexmedetomidine in Total Knee Arthroplasty

Comparison of the Efficacy and Safety of Three Adjuvant Strategies for ACB and iPACK Blocks in Patients Undergoing Elective Total Knee Arthroplasty: A Prospective, Randomized Clinical Trial

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Sep 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Poznan University of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective randomized controlled trial aims to compare the analgesic efficacy and safety of three adjuvant strategies for ultrasound-guided Adductor Canal Block (ACB) and iPACK block in patients undergoing elective total knee arthroplasty under spinal anesthesia. All participants will receive standardized spinal anesthesia with 0.5% ropivacaine combined with ACB and iPACK blocks using 0.2% ropivacaine. Patients will be randomized into one of three groups: standard ACB + iPACK without adjuvants, ACB + iPACK with intravenous dexamethasone 8 mg, or ACB + iPACK with intravenous dexamethasone 8 mg combined with perineural dexmedetomidine added to both regional blocks. The primary outcome will be total postoperative opioid consumption during the first 48 hours after surgery expressed as intravenous morphine equivalents. Secondary outcomes will include pain intensity at rest and during movement, duration of analgesia, time to first rescue analgesia, quadriceps muscle strength, early mobilization, adverse events, inflammatory markers, and length of hospital stay.

Conditions

  • Knee Osteoarthritis

Interventions

  • Ropivacaine 0.2% Injectable SolutionDrug

    Ropivacaine 0.2% used for ultrasound-guided ACB and iPACK blocks (20 mL per block).

  • DexamethasoneDrug

    Intravenous dexamethasone 8 mg administered perioperatively.

  • DexmedetomidineDrug

    Perineural dexmedetomidine 12.5 μg added to each regional block (ACB and iPACK).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total postoperative opioid consumption during the first 48 hours after surgeryTime frame: 48 hours after surgery

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The John Paul II Catholic University of Lublin

    Lublin, Poland · Recruiting

  • Poznan University of Medical Sciences

    Poznan, Poland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.